Information Provided By:
Fly News Breaks for February 6, 2020
PODD
Feb 6, 2020 | 07:36 EDT
Raymond James analyst Jayson Bedford raised his price target for Insulet to $213 from $158, saying the company remains one of the highest quality growth stories in his coverage with momentum in its base diabetes business accelerating and profitability improving. The analyst says he expects growth in the pump market to accelerate and expect Insulet to capture market share. He made no change to his Outperform rating.
News For PODD From the Last 2 Days
There are no results for your query PODD